Abbott Laboratories (ABT), boasting a market capitalization of $159.97 billion, spearheads the global arena of healthcare product innovation. Its multifaceted operations are partitioned into four key segments: Established Pharmaceutical Products; Diagnostic Products; Nutritional Products; and Medical Devices.
ABT is scheduled to release its fiscal third-quarter financial results on October 18. Wall Street expects the company to report earnings of $1.10 per share for the quarter. Its revenue for the quarter is expected to come in at $9.82 billion. In addition, I have evaluated what makes the investment case strong for ABT in this article.
